DIRS.INFO The most relevant business & tech news

But J&J's drug is walking away with a notable edge over its rival. They add more options to a growing arsenal of treatments that have helped improve outcomes for people with multiple myeloma. But the new approvals also give J&J's therapy, which was developed with Legend Biotech, a clear advantage over Bristol Myers's drug. J&J's drug has gradually gained ground over Abecma in the CAR-T market for multiple myeloma, even though it first entered the market a year later. With the new approval on Friday, Jefferies' Shi expects J&J's drug to win the majority of that market share.

Persons: Jonathan Raa, Johnson, Myers's, Bristol Myers, Jefferies, Kelly Shi, Shi, Carvykti, Cantor Fitzgerald, Rick Bienkowski, Kelsey Goodwin, Annika, annikakim.constantino@nbcuni.com Organizations: Nurphoto, Bristol Myers Squibb, Johnson, Food and Drug Administration, FDA, Legend Biotech, Bristol, New York Stock Exchange, NYSE, Reuters, Mount Sinai Hospital, Getty Locations: Bristol, U.S, EU, Japan, Mount Sinai, New York City

☆ Here are Wednesday's biggest analyst calls: Nvidia, Tesla, Super Micro, Coinbase, Apple, Microsoft, Rivian & more
▼ + stars: | 2024-03-13 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

"We are initiating coverage of Legend Biotech (LEGN) with an Outperform rating and a price target of $86." Bank of America reiterates Super Micro as buy Bank of America raised its price target on Super Micro to $1,280 per share from $1,040. The firm has an outperform rating on shares of Boeing. We Initiate with a Buy rating and $15 PT." "We initiate coverage of IMVT with a Buy rating and 12-month price target of $50 (60% upside potential)."

Persons: Raymond James, it's, Wells, Tesla, Davidson, Goldman Sachs, Goldman, Baird, Bernstein, TXRH, EBITDA, Jefferies, underperform Jefferies, Baird downgrades Fiserv, Stephanie Ferris, Charles Drucker, helms, Cooper, William Blair, BTIG, Bitdeer, JMP, Morgan Stanley, Idacorp, Rivian Organizations: Biotech, Legend Biotech, Citi, Constellation Brands Citi, Constellation, Watch, Nielsen, DA, " Bank of America, Bank of America, Nvidia, GPU Tech Conference, TAM, Royal Caribbean, Boeing, Apple, Moelis, Company, RBC, Pointe, GM, Microsoft, ROIC, Jefferies, FIS, JPMorgan, Cooper Companies, Bitdeer Technologies, Technology, ICE, of America, Argus Locations: Nice, Texas, Cleveland, Southwest, Kansas, Missouri

☆ Stocks making the biggest moves midday: Tesla, GE HealthCare, Coinbase and more
▼ + stars: | 2024-03-13 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Crypto stocks — Stocks whose performance is tied to the price of bitcoin rose as the cryptocurrency pushed to another record for the third day in a row. Dollar Tree posted adjusted earnings of $2.55 per share on $8.64 billion of revenue for the fourth quarter. Analysts surveyed by LSEG, formerly known as Refinitiv, had penciled in $2.65 per share on $8.67 billion in revenue. GE HealthCare — Shares dropped 3% after the medtech company announced a secondary offering of 13 million shares. Analysts had expected earnings of 2 cents per share on revenue of $1.62 billion, per LSEG.

Persons: Coinbase, MicroStrategy, CleanSpark, Baird, Goldman Sachs, Wells, Raymond James, —, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Pia Singh, Michelle Fox Organizations: Marathon, Iris Energy, Texas, Nvidia, Devices, Micron Technology —, Micron, AMD, LSEG, GE, —, GE HealthCare Technologies, General Electric, Royal, Petco, Wellness Locations: Kentucky, Royal Caribbean

☆ US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
▼ + stars: | 2023-11-20 | by ( ) www.reuters.com time to read: +2 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The U.S. Food and Drug Administration (FDA) has not yet confirmed when the advisory panel would meet, they added. Shares of Bristol Myers Squibb fell more than 2% and those of 2seventy bio slid nearly 20% in early morning trade. The therapy was originally co-developed by bluebird bio (BLUE.O) but following its spin-off in 2021 became part of 2seventy's portfolio. Bristol Myers and 2seventy bio, however, have faced manufacturing constraints, and a month-long planned maintenance shutdown of one of Abecma's manufacturing facility in June had also negatively impacted sales.

Persons: Andrew Kelly, 2seventy bio's, Bristol Myers, Johnson, Biotech's, Khushi, Sriraj Kalluvila Organizations: Food and Drug Administration, FDA, REUTERS, Bristol Myers Squibb, U.S . Food, Drug Administration, Bristol, Johnson, Thomson Locations: White Oak , Maryland, U.S, Bengaluru

☆ Goldman says this biotech could become a global cell therapy leader, has nearly 40% upside
▼ + stars: | 2023-11-06 | by ( Alex Harring | ) www.cnbc.com time to read: +1 min

Legend Biotech has a best-in-class product and could become a global leader in the cell and gene therapy space, according to Goldman Sachs. "We believe Legend has the potential to grow into a leading global cell therapy company," Chen said in a note to clients. Its leading therapy in the space is Carvykti, which he described as "best-in-class." In partnership with Johnson & Johnson , Carvykti is undergoing capacity expansion in the U.S. and European Union to meet demand. Legend stock rose 0.3% in Monday's session.

Persons: Goldman Sachs, Ziyi Chen, Chen, Johnson, Carvykti, — CNBC's Michael Bloom Organizations: Biotech, Johnson, Union Locations: U.S

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Amazon, BJ's, Ferrari, Disney, Birkenstock & more
▼ + stars: | 2023-11-06 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Monday's biggest calls on Wall Street: KBW upgrades Bank of America to market perform from underperform KBW upgraded the banking giant with long-term rates declining. Bank of America downgrades Paramount to underperform from buy Bank of America said the backdrop is too challenging for the media stock. Bank of America reiterates Nvidia as buy Bank of America said it's bullish on the stock heading into earnings later this month. Goldman Sachs initiates Birkenstock as buy Goldman initiated the shoe company with a buy and said Birkenstock shares are compelling. Bank of America reiterates Apple as neutral Bank of America said it's sticking with its neutral rating on shares of Apple .

Persons: KBW, Mizuho, it's, BILI, Lee jeans, it's bullish, Goldman Sachs, Goldman, EBITDA, Raymond James downgrades Bloomin, Raymond James Organizations: Bank of America, Underperform, Corp, Deutsche Bank, Deutsche, Mizuho, TAM, UBS, Amazon, Citi, Disney, " Bank of America, Paramount, Barclays, Nvidia, AMD, Dominion, Biotech, JPMorgan, HSBC, RBC, Apple, of America Locations: China, FY24E, CLX, Russia, Ukraine

☆ 2seventy bio to lay off 40% of workforce; CEO to step down
▼ + stars: | 2023-09-12 | by ( ) www.reuters.com time to read: +2 min

Nick Leschly, CEO of bluebird, speaks at the opening of Lonza Houston, the world’s largest dedicated cell and gene therapy facility, in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer Acquire Licensing RightsSept 12 (Reuters) - 2seventy bio (TSVT.O) said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma, lifting the company's shares more than 8% in premarket trade. The company added that CEO Nick Leschly will step down and transition to the role of chairman. Leschly was earlier the CEO of bluebird bio (BLUE.O) for 11 years, but changed role after the gene therapy maker's oncology portfolio was spun off from it as 2seventy. The company will now focus on another type of multiple myeloma patients, for which it expects approval from the U.S. Food and Drug Administration in mid-December.

Persons: Nick Leschly, Lonza, Daniel Kramer, Leschly, 2seventy, Abecma, Johnson, Bristol Myers, William Baird, Pratik Jain, Shounak Dasgupta, Maju Samuel Organizations: bluebird, REUTERS, Johnson, Legend Biotech, Bristol, Bristol Myers Squibb, U.S . Food, Drug Administration, Thomson Locations: Lonza Houston, Houston , Texas, U.S, Abecma, Bengaluru

☆ ASCO conference will put the focus on the fight against cancer. These stocks are in the spotlight
▼ + stars: | 2023-05-28 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world's biggest cancer research conference in Chicago, starting Thursday. The pair has already has won regulatory approval for Enhertu for metastatic HER2-low breast cancer, but the companies are also studying its use in a variety other HER2 tumors in breast cancers. Lilly's drug, Verzenio, is used in high-risk patients with HR-positive HER2-negative breast cancer that is more likely to reoccur and has already breached the patient's lymph nodes. In a research note earlier this month, Guggenheim analyst Seamus Fernandez said Kisqali is already taking market share from Pfizer's Ibrance in metastatic breast cancer. Merck's Keytruda is also being watched for what benefits it could offer early-stage lung cancer patients .

☆ Wall Street analysts love these emerging market stocks that all trade in the U.S.
▼ + stars: | 2023-03-30 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

While U.S. and European investors continue to navigate a banking crisis, high inflation and slower earnings growth, a host of emerging markets stocks beloved by Wall Street analysts are expected to surge higher. Emerging markets equities had an optimistic start to the year as China reopened its economy, and as high inflation showed signs of easing. In 2023, the iShares MSCI Emerging Markets ETF (EEM) is up 4.4% through Thursday's open. In fact, some emerging markets stocks that are also listed in the U.S. could be due for huge upside. These names are included in exchange traded funds such as the the iShares MSCI Emerging Markets ETF, Vanguard FTSE Emerging Markets ETF, iShares Core MSCI Emerging Markets ETF, the Schwab Emerging Markets Equity ETF or the SPDR Portfolio Emerging Markets ETF.

☆ Here are Friday's biggest analyst calls: Nvidia, Tesla, Wendy's, Microsoft, Coinbase, Netflix & more
▼ + stars: | 2023-03-24 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Here are Friday's biggest calls on Wall Street: UBS reiterates Tesla as buy UBS said it's recent survey checks show Tesla is "best positioned" to win the EV race. Wells Fargo reiterates Microsoft as a top AI pick Wells said Microsoft is one of the biggest beneficiaries of AI. Jefferies downgrades UBS to hold from buy Jefferies said it sees too much uncertainty after the banking giant's acquisition of Credit Suisse. Jefferies upgrades Regeneron to buy from hold Jefferies said it's bullish on several of the pharmaceutical company's products. Citi reiterates Nvidia as buy Citi said Nvidia is a top beneficiary of AI.

☆ These are Wall Street analysts' favorite global stocks for U.S. investors
▼ + stars: | 2023-03-05 | by ( Fred Imbert | ) www.cnbc.com time to read: +2 min

Nearly 70% of analysts covering the stock rate it a buy, with the average price target implying upside of roughly 20%. The average price target on Legend Biotech implies upside of 56.6%. More than 81% of analysts covering the stock rate it a buy. Streaming company Joyy made the list as well, with nearly 80% of analysts covering the stock rating it as buy. The average price target on the stock implies upside of 44%.

☆ This emerging markets fund outperforms by finding ideas in small- and mid-cap companies
▼ + stars: | 2023-03-01 | by ( Sarah Min | ) www.cnbc.com time to read: +7 min

A keen appreciation for ideas that fly under the radar helped one emerging markets fund outperform during the pandemic. Since starting at the Matthews Emerging Markets Small Companies (MSMLX) fund in 2020, Vivek Tanneeru said he has kept his focus on small- and mid-cap companies to generate alpha (returns above a benchmark). For example, his Matthews Emerging Markets Sustainable Future fund (MISFX) fund, which he founded in 2015, is also given five stars at Morningstar. One stock Tanneeru is particularly bullish on now is Legend Biotech . For Tanneeru, small caps are a more nimble way for investors to gain access to emerging markets and tap into consumer preferences there.

☆ Biotech stocks that could surge more than 35% include one name targeting treatments for schizophrenia
▼ + stars: | 2023-02-09 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Still, the outlook for biotech stocks could improve now , with innovation in new drugs and more merger and acquisition activity driving investor interest. Recently, Wall Street has been zoning in on developments in treatments for Alzheimer's diseases, drugs for weight loss and treatments using gene editing. CNBC Pro screened for biotech stocks that are part of the iShares Biotechnology ETF , searching for names with huge upside from current prices. In January, Piper Sandler initiated research coverage of Karuna with an overweight rating, saying it's "blazing a new trail in Schizophrenia" treatments. The stock was named another top 2023 pick by Piper Sandler, which said Legend has a "best-in-class" treatment for adults with relapsed multiple myeloma, a segment "with demand far outpacing supply."

☆ Here are Tuesday's biggest analyst calls: Apple, Amazon, Nike, Monster, AMD, Carvana, CVS & more
▼ + stars: | 2022-11-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Here are Tuesday's biggest calls on Wall Street: Bank of America reinstates Deckers as buy Bank of America called Deckers a "rare, consistent compounder." Deutsche Bank reiterates Amazon as buy Deutsche said "macro challenges are no doubt pressuring ad budgets" for Amazon, but the company continues to be well positioned. JPMorgan upgrades Carvana to neutral from underweight JPMorgan said in its upgrade of the stock that risks are now better understood. JPMorgan upgrades Monster to outperform from neutral JPMorgan said the beverage giant has an "attractive narrative." Bank of America reiterates Advanced Micro Devices as buy Bank of America said shares of AMD are attractive heading into earnings Tuesday afternoon.

Search resuls for: "Legend Biotech"

14 mentions found